1-3 of 3
Stephan Oertel, MD
Close
Sort by
Journal Articles

Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.

Ralf Trappe, MD, Sylvain Choquet, MD, Stephan Oertel, MD, Veronique LeBlond, MD, Tor Ekman, MD, Monica Sender, MD, Peter Molle, MD, Petra Reinke, MD, Hans Lehmkuhl, MD, Manfred Hummel, MD, Sven Jonas, MD, Ruth Neuhaus, MD, Gilles Salles, MD, Franck Morschhauser, MD, Arnaud Jaccard, MD, Daan Dierickx, MD, Ionannis Anagnostopoulos, MD, Martine Raphael, MD, Hanno Riess, MD
Journal: Blood
Blood (2007) 110 (11): 390.
https://doi.org/10.1182/blood.V110.11.390.390
Published: 2007
Journal Articles

Fixed-Dose Single Administration of Pegfilgrastim vs Daily Filgrastim in Patients with PTLD Undergoing a Sequential Therapy of Rituximab and CHOP Chemotherapy.

Ralf Trappe, MD, Papp-Vary Matthias, Stephan Oertel, MD, Riess Hanno, MD
Journal: Blood
Blood (2005) 106 (11): 4724.
https://doi.org/10.1182/blood.V106.11.4724.4724
Published: 2005
Journal Articles

Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study.

Ralf Trappe, MD, Stephan Oertel, MD, Sylvain Choquet, MD, Vernoique LeBlond, MD, Matthias Papp-Vary, Hanno Riess, MD
Journal: Blood
Blood (2005) 106 (11): 932.
https://doi.org/10.1182/blood.V106.11.932.932
Published: 2005